The upcoming earnings report for Bio-Techne Corporation (TECH) is set for Tuesday, May 5th, with a consensus estimate EPS of $0.55.
Bio-Techne Corporation (TECH) is currently priced at $53.63, experiencing a price drop of $1.48 (-2.69%) from the previous close of $55.11. Trading volume stands at $262,720, representing a 11.25% increase compared to the average.
The latest quarterly earnings report for TECH was on Tuesday, February 3rd, with a consensus estimate EPS of $0.43. Further details on revenue and profit margins are awaited.
TECH offers a forward dividend yield of 0.597%, with a dividend per share MRQ of 8 cents and TTM of 32 cents.
Key cash flow figures for TECH include a free cash flow of $76.49 million, operating cash flow of $82.41 million, and a net change in cash of $27.92 million.
TECH reported a revenue of $295.88 million, gross profit of $191.28 million, and a net income of $38 million, with an EPS of 24 cents.
Notable ratios for TECH include a net profit margin of 12.85%, return on equity of 1.89%, and a price-to-earnings ratio of 60.28.
TECH showcases total assets of $2.52 billion, total liabilities of $511.71 million, and net debt of $178 million.
This real-time financial report provides insights into TECH's current status and upcoming earnings, guiding investors in evaluating their investment decisions.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.